87
Views
37
CrossRef citations to date
0
Altmetric
Original Research

Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance

, &
Pages 561-569 | Published online: 15 Apr 2016
 

Abstract

Background

Oral monotherapy anticoagulation has facilitated home treatment of venous thromboembolism (VTE) in outpatients.

Objectives

The aim of this study was to measure efficacy, safety, as well as patient and physician perceptions produced by a protocol that selected VTE patients as low-risk patients by the Hestia criteria, and initiated home anticoagulation with an oral factor Xa antagonist.

Methods

Patients were administered the Venous Insufficiency Epidemiological and Economic Study Quality of life/Symptoms questionnaire [VEINEs QoL/Sym] and the physical component summary [PCS] from the Rand 36-Item Short Form Health Survey [SF36]). The primary outcomes were VTE recurrence and hemorrhage at 30 days. Secondary outcomes compared psychometric test scores between patients with deep vein thrombosis (DVT) to those with pulmonary embolism (PE). Patient perceptions were abstracted from written comments and physician perceptions specific to PE outpatient treatment obtained from structured survey.

Results

From April 2013 to September 2015, 253 patients were treated, including 67 with PE. Within 30 days, 2/253 patients had recurrent DVT and 2/253 had major hemorrhage; all four had DVT at enrollment. The initial PCS scores did not differ between DVT and PE patients (37.2±13.9 and 38.0±12.1, respectively) and both DVT and PE patients had similar improvement over the treatment period (42.2±12.9 and 43.4±12.7, respectively), consistent with prior literature. The most common adverse event was menorrhagia, present in 15% of women. Themes from patient-written responses reflected satisfaction with increased autonomy. Physicians’ (N=116) before-to-after protocol comfort level with home treatment of PE increased 48% on visual analog scale.

Conclusion

Hestia-negative VTE patients treated with oral monotherapy at home had low rates of VTE recurrence and bleeding, as well as quality of life measurements similar to prior reports.

Author contributions

JAK conceived and designed the study, performed primary analysis, and wrote the first draft of the manuscript. DMB participated in development of the protocol and implementation of the protocol, wrote the manuscript, collected data, and performed analysis. ZPK edited the protocol, collected and analyzed the data, helped write, and edit the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure

In the past 3 years, JAK has received research grant funding from the Patient-Centered Outcomes Research Institute and the National Institutes of Health, Mallingkrodt in addition to being a consultant to Janssen Pharmaceuticals. The other authors report no conflicts of interest in this work.